Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Puran Chen

Showing results (31-40 of 43) with videos related to

Pageof 5
Sort By:
Cell Host & Microbe|January 11, 2024
Memory T cells effectively recognize the SARS-CoV-2 hypermutated BA.2.86 variantThomas R Müller, Yu Gao, Jinghua Wu, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 22, 2021
Major alterations in the mononuclear phagocyte landscape associated with COVID-19 severityEgle Kvedaraite, Laura Hertwig, Indranil Sinha, et al.
The Journal of Infectious Diseases|February 29, 2024
Type I Interferon Autoantibodies Correlate With Cellular Immune Alterations in Severe COVID-19Benedikt Strunz, Christopher Maucourant, Adi Mehta, et al.
Clinical & Translational Immunology|February 13, 2026
The impact of B-cell reconstitution on mRNA vaccine responses in allogeneic stem cell transplant recipientsFredrika Hellgren, Rodrigo Arcoverde Cerveira, Gustaf Lindgren, et al.
Science Translational Medicine|July 12, 2023
Additive effects of booster mRNA vaccination and SARS-CoV-2 Omicron infection on T cell immunity across immunocompromised statesThomas R Müller, Takuya Sekine, Darya Trubach, et al.
Med (New York, N.Y.)|January 25, 2022
Salivary IgG to SARS-CoV-2 indicates seroconversion and correlates to serum neutralization in mRNA-vaccinated immunocompromised individualsKatie Healy, Elisa Pin, Puran Chen, et al.
Ebiomedicine|December 3, 2021
Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trialPeter Bergman, Ola Blennow, Lotta Hansson, et al.
Respiratory Research|February 24, 2023
Targeted plasma proteomics reveals signatures discriminating COVID-19 from sepsis with pneumoniaLaura M Palma Medina, Haris Babačić, Majda Dzidic, et al.
European Journal of Immunology|November 27, 2021
COVID-19-specific metabolic imprint yields insights into multiorgan system perturbationsMartin Cornillet, Benedikt Strunz, Olav Rooyackers, et al.
Molecular Medicine (Cambridge, Mass.)|February 9, 2022
NK cell frequencies, function and correlates to vaccine outcome in BNT162b2 mRNA anti-SARS-CoV-2 vaccinated healthy and immunocompromised individualsAngelica Cuapio, Caroline Boulouis, Iva Filipovic, et al.
Pageof 5

Showing results (31-40 of 43) with videos related to

Sort By:
Pageof 5
Cell Host & Microbe|January 11, 2024
Memory T cells effectively recognize the SARS-CoV-2 hypermutated BA.2.86 variantThomas R Müller, Yu Gao, Jinghua Wu, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 22, 2021
Major alterations in the mononuclear phagocyte landscape associated with COVID-19 severityEgle Kvedaraite, Laura Hertwig, Indranil Sinha, et al.
The Journal of Infectious Diseases|February 29, 2024
Type I Interferon Autoantibodies Correlate With Cellular Immune Alterations in Severe COVID-19Benedikt Strunz, Christopher Maucourant, Adi Mehta, et al.
Clinical & Translational Immunology|February 13, 2026
The impact of B-cell reconstitution on mRNA vaccine responses in allogeneic stem cell transplant recipientsFredrika Hellgren, Rodrigo Arcoverde Cerveira, Gustaf Lindgren, et al.
Science Translational Medicine|July 12, 2023
Additive effects of booster mRNA vaccination and SARS-CoV-2 Omicron infection on T cell immunity across immunocompromised statesThomas R Müller, Takuya Sekine, Darya Trubach, et al.
Med (New York, N.Y.)|January 25, 2022
Salivary IgG to SARS-CoV-2 indicates seroconversion and correlates to serum neutralization in mRNA-vaccinated immunocompromised individualsKatie Healy, Elisa Pin, Puran Chen, et al.
Ebiomedicine|December 3, 2021
Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trialPeter Bergman, Ola Blennow, Lotta Hansson, et al.
Respiratory Research|February 24, 2023
Targeted plasma proteomics reveals signatures discriminating COVID-19 from sepsis with pneumoniaLaura M Palma Medina, Haris Babačić, Majda Dzidic, et al.
European Journal of Immunology|November 27, 2021
COVID-19-specific metabolic imprint yields insights into multiorgan system perturbationsMartin Cornillet, Benedikt Strunz, Olav Rooyackers, et al.
Molecular Medicine (Cambridge, Mass.)|February 9, 2022
NK cell frequencies, function and correlates to vaccine outcome in BNT162b2 mRNA anti-SARS-CoV-2 vaccinated healthy and immunocompromised individualsAngelica Cuapio, Caroline Boulouis, Iva Filipovic, et al.
Pageof 5